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ABSTRACT
AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppression.
Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative disease. In
the era of potent antiretrovirals therapy (ARV), the malignant complications due to HIV-I infection have decreased in
developed nations where ARV is administered, but still poses a major problem in developing countries where HIV-l
incidence is high and ARV is still not yet widely available. Even in ARV treated individuals there is a concern that the
prolonged survival of many HIV-l carriers is likely to eventually result in an increased number ofmalignancies diagnosed.
Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma (KS), Hodgkin's
disease (HD) and non-Hodgkin's lymphoma (NHL). The incidence ofNHL has increased nearly 200 fold in HIV-positive
patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of
HAART therapy. These AIDS related lymphomas are distinct from their counterparts seen in HIV-l seronegative patients.
For example nearly half ofall cases ofARL are associated with the presence ofa gamma herpesvirus, Epstein Barr virus
(EBV) or human herpesvirus-8 (HHV-8)/ Kaposi's sarcoma associated herpesvirus (KSHV). The pathogenesis of ARLs
is complex. B-cell proliferation driven by chronic antigenemia resulting in the induction of polyclonal and ultimately
monoclonal lymphoproliferation may occur in the setting of severe immunosuppression.
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INTRODUCTION
It has been over twenty years since the onset of the
AIDS epidemic, and in spite of the tremendous progress
made towards the understanding of the disease, the virus
that causes the disease and the development of highly ef-
fective anti-retroviral treatments, the number of people
infected by HIV is still staggering. As of the end of2004,
it was estimated that there were 39.4 million people newly
infected with HIV, and 3.1 million deaths globally (www.
UNAIDS.org). Over 2/3 of infections occur in the devel-
oping world and sub-Saharan Africa. Concurrent with
immunosuppression in the infected individuals are oppor-
tunistic infections and AIDS-associated diseases, includ-
ing malignancies, which have increased substantially dur-
ing the AIDS disease course [1, 2]. Malignancies that were
found to have high incidence of HIV-infected individuals
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are Kaposi's sarcoma (KS), Hodgkin's disease (HD), non-
Hodgkin's lymphoma (NHL), squamous cell carcinomas,
plasmacytomas, and leiomyosarcoma in children. These
tumors arose due to the lack of appropriate immune re-
sponse or the reactivation of etiological agents associate
with these tumors in immunosuppressed HIV infected
individuals. Serveral AIDS-associated malignancies were
found to be associated with the viral infections. Among
them, Epstein-Barr virus (EBV) was found to associate
with NHL, HD, and leiomyosarcoma; Kaposi's sarcoma
associated herpesvirus (KSHV) or human herpesvirus-8
(HHV-8) was found to associate with KS and primary ef-
fusion lymphoma(PEL), and human papilloma virus (HPV)
was found to associate with squamous cell neoplasia. The
most common malignancies seen in HIV-infected individu-
als are KS and HNL, and both have been classified as AIDS-
defining illnesses.
AIDS RELATED LYMPHOMAS
The infectious and malignant complications ofHIV have
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decreased in developed nations where potent antiretrovirals
(ARV) are widely available. However, the prolonged sur-
vival of many HIV carriers is likely to eventually result in
an increased number of malignancies diagnosed in these
individuals. Chronically immunocompromised patients
have a markedly increased risk of developing Iympho-
proliferative disease. The incidence of non-Hodgkin's lym-
phomas (NHL) is increased nearly 200 fold in HIV-posi-
tive patients and accounts for a greater percentage of AIDS
defining illness in the US since the advent of HAART
therapy [3, 4]. AIDS related lymphomas (ARLs) are dis-
tinct from their counterparts seen in HIV seronegative
patients. For example nearly half of all cases of ARL are
associated with the presence of a gamma herpesvirus, EBV
or HHV-8 [5]. ARLs are often diagnosed at a very ad-
vanced stage and frequently involve uncommon sites (oral
cavity, GI tract, central nervous system) [5, 6]. The patho-
genesis ofARLs is complex. B-cell proliferation driven by
chronic antigenemia results in the induction of polyclonal,
and ultimately monoclonallymphoproliferation. In addi-
tion dysregulation of cytokine pathways (interleukin-6 and
interleukin-l0), coupled with bcl-6, p53, and c-myc mu-
tations have been implicated in the pathogenesis of ARL
[7].
SUBTYPES OF AIDS NHLS
AIDS NHLs may be broadly categorized into several
subtypes. Large cell immunoblastic lymphoma (ffiL) and
diffuse large cell lymphoma (DLCL) generally occur in
the setting of moderate to severe immunosuppression
(CD4+ lymphocyte counts below 100 mmvrnl). IBLs and
to a lesser degree DLCLs are often associated with EBV.
These tumors express the EBV encoded oncoprotein la-
tent membrane protein-l (LMP-l) [5-7]. LMP-l may func-
tion in a similar manner to tumor necrosis factor recep-
tors by activating cellular anti-apoptotic factors such as
Nuclear Factor Kappa B [6, 7]. DLCLs are frequently
found to contain genetic alterations in Bcl-6 [8] although
the consequences of these mutations have not been fully
defined.
AIDS related Burkitt's lymphoma (BL) generally oc-
curs in more immunocompetent patients [9]. AIDS BLs
share features with endemic African BL in that both
overexpress c-myc due to reciprocal translocations that
bring the transactivator under the influence of potent pro-
moter sequences within the immunoglobulin (Ig) genes
loci. Inactivating mutations and deletions ofp53 are also
common as in all types of BL [10]. A distinguishing fea-
ture between AIDS related and endemic BL is that the
former is associated with EBV far less frequently than the
latter [9,10]. These tumors are incredibly aggressive with
brief doubling times. Flow cytometric analysis typically
reveals that over 90% are in S phase. Ongoing tumor lysis
syndrome even in the absence of concomitant chemotherapy
is often noted. AIDS related BLs appear to carry a poor
prognosis even when compared to AIDS related DLCL
[11 ].
A recently described variant of ARL, plasmablastic
lymphoma, occurs in a small percent ofHIV+ patients.
These tumors are generally associated with EBV and HHV-
8 (10). Response to conventional chemotherapy is poor
and some investigators have suggested that viral targeted
approaches may be beneficial [12].
A rapidly fatal subtype of AIDS NHL is Primary Central
Nervous System Lymphoma (PCNSL). These tumors are
most frequently classified as IBLs and occur in the most
immunosuppressed patients. In contrast to PCNSL in HIV
negative patients they are virtually always associated with
EBV [13]. Detection ofEBV sequences in theCSF by poly-
merase chain reaction (PCR) coupled with positive Thal-
lium spectroscopy has proven to be a helpful diagnostic
tool [14]. These patients are often afflicted by many com-
plications of HIV infection. Standard therapy with con-
ventional chemotherapy combined with radiation therapy
results in only about a 4 month survival although long term
remission has been reported in patients treated with high
dose Zidovudine and Ganciclovir [15, 16].
The most commonly identified virus associated with
AIDS related lymphomas is EBV and there is a large body
of published work on the oncogenic mechanisms of this
agent [17, 18]. B-Iymphocytes transformed by EBV
(lymphoblastoid cell lines) in vitro express an array of vi-
rus-encoded proteins including six EBV nuclear antigens
(EBNAs) and three LMPs. EBNAs are generated from dif-
ferential splicing of a transcript that arises from one of
two promoters (Cp or Wp) [18]. This form of latency is
termed Latency III. This form of latency is common in
immunoblastic lymphomas [17]. A Type II form oflatency
where EBNA 1, LMP-l and LMP-2a are expressed has
been identified in some EBV associated lymphomas. In
Latency I (typical of Burkitt lymphomas) only EBNA-l
(generated from the Qp promoter) and EBERs are ex-
pressed [17, 18]. Recent studies have indicated that some
heterogeneity in EBV gene expression and EBNA promoter
usage exists among endemic BL [19].
THERAPY OF AIDS NHL
Treatment of the AIDS NHL remains disappointing.
Polychemotherapy regimens have produced similar results
although regimens that combine potent antiretrovirals with
conventional chemotherapy may prove superior [20]. HIV
positivepatients often have poor bone marrow reserve which
compromises the ability to deliver full dose chemotherapy.
Concomitant opportunistic infections may also lead to a
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decrease in chemotherapy delivery. In general, response
and survival rates for common NHL regimens are lower
than for an HIV negative population. Complete responses
occur but tend to be of shorter duration with frequent
relapses. Our experience has been that patients concomi-
tantly diagnosed with HIV infection and lymphomas do
better with antiretroviral and anti-lymphoma therapy than
do those who develop lymphoma after becoming refrac-
tory to antiretrovirals. A recently completed study per-
formed by the NCI sponsored AIDS malignancy consor-
tium (AMe) demonstrated the feasibility of concomitant
chemotherapy with HAART [21]. Probably the best re-
ported results for chemotherapy in AIDS NHL were from
Dr. Little's group at the National Cancer Institute. Using
the EPOCH regimen, the group achieved remission in 22
of24 patients with a progression free survival of23 months.
These patients had favorable prognostic factors (median
CD4+ lymphocyte count of233 mmvml) [20]. Enhanced
toxicity of rituximab and CHOP chemotherapy was re-
cently noted in a large multi-center trial conducted by the
AMC [22]. The addition of rituximab to standard-dose
CHOP as compared to CHOP alone led to increased infec-
tious complications and deaths attributable to sepsis. It is
possible that delayed recovery ofhumoral immunity could
contribute to this increased risk of life-threatening bacte-
rial infections in HIV-infected patients. There have been
several reports on the feasibility and efficacy of high dose
chemotherapy and autologous stem cell transplant for ARL
[23,24]. It is reasonable to assume that patients with well
controlled HIV and good performance status should be
considered candidates for this therapy. Newer approaches
that may benefit patients with ARL include EBV specific
cytotoxic T cel1s and agents that activate the lytic pro-
gram of gamma herpesviruses thereby sensitizing the tu-
mors to antivirals [25, 26].
KAPOSI's SARCOMA
Kaposi's sarcoma was first described by Moritz Kaposi
in 1872 in several cases of multi-focal pigmented sarcoma
in elderly Mediterranean men. There are four forms of
KS. The first is known as the classic KS or sporadic KS.
They are mainly found in the elderly male population in
Mediterranean countries, such as Italy [28]. The lesions
tend to be found in the lower extremities and are generally
non-aggressive. The second type is known as the endemic-
African KS; it is more aggressive than the classic KS and
can also involve the lymph nodes. This form of KS was
seen in the African continent prior to the HIV epidemic
and was found in adults (both male and female) and in
children [29]. The third is the iatrogenic form ofKS, which
normally occurs after transplantation in patients treated
with immunosuppressive medication. This form of KS
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seems to vary in geographical prevalence, and is more
common in individuals of Mediterranean descent [30]. The
fourth form ofKS is the AIDS-KS. This is a very aggres-
sive type ofKS, first described in early 1980's in homo-
sexual men [31]. AIDS-KS not only involves skin, but also
the lymph nodes and often disseminates to lungs, gas-
trointestinal track, liver, and spleen.
KS is composed of a mixture of irregular shaped, round
capillaries, and slit-like endothelium-lined vascular spaces
and spindle-shape cells with infiltrating mononuclear cells.
It is not clear whether KS represents a clonal neoplastic
process or a polyclonal inflammatory lesion. Studies have
shown that varying monclonality, oligoclonality, and
polyclonality from lesions of various patients [32]. The
origin of the KS spindle cells is also not clear; it has been
suggested that KS cel1s represent a heterogeneous popula-
tion of cells, arising from a pluripotent mesenchmal pre-
cursor cel1s, and may be oflymphatic endothelial cell ori-
gin [33].
HUMAN HERPESVIRUS AND KS
An infectious agent has long been suspected in the de-
velopment ofKS; herpesvirus-like particles were found in
short-term KS tissue culture, and were subsequently iden-
tified as cytomegalovirus [34], but the involvementofCMV
in KS has not been confirmed. In 1994, a novel human
herpesvirus was identified by Chang and Moore [35] us-
ing representational difference analyses. This virus is now
known as KSHV or HHV-8, it is found to be necessary but
not sufficient for the development of all types of KS. It is
clear that other co-factors, such as immunosuppression,
are required for KS development. KSHV is found in all KS
lesions, and is mainly located in the vascular endothelial
cells and perivascular spindle-shaped cells [36]. KSHV
infection is not commonly found in low-risk population
but found commonly in individuals at risk for KS.
KSHV belongs to the y-herpesvirus family, which can
further be divided into two subgroups, y-l or
lymphocrytovirus and y-2 or rhadinovirus. EBV is the pro-
totype of y-l virus and the simian herpesvirus saimini is
the prototype ofy-2 herpesvirus [37]. KSHV is classified
as a y-2 rhadinovirus and is the first human virus of this
subfamily identified. Like other herpesviruses, HHV-8 is a
double-stranded deoxyribonucleic acid (DNA) virus. Its
genome is linear, is about 165 kbp in length, and contains
at least 87 viral genes. A feature of some DNA viruses,
particularly of herpesviruses and KSHV, is the ability of
these viruses to incorporate or pirate host genes into their
genome: these genes can then playa role in the replication,
survival, and transformation functions of the virus. KSHV
was found to encode human homologue genes that regu-
late cell cycling like cyclin D, growth factors like
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interleukin 6, or genes that may prevent programmed cell
death such as bcl-2. Deciphering the functions of these
viral genes will lead to a better understandingof viral patho-
genesis and oncogenesis.
Unlike most other herpesviruses, KSHV infection does
not seem to be widely distributed in most populations.
The detection of KSHV infection relies on the presence of
antibodies against either lytic and/or latent antigens and
varies among the different tests that were used in differ-
ent seroprevalence studies. In general, the frequency of
infection appears to be low in North America, certain Asian
countries, and in Northern European nations such as the
United Kingdom and Germany, with most studies report-
ing a seroprevalence rate in normal blood donors of less
than 5% [2, 38-40]. In these countries the seroprevalence
of KSHV in different risk groups mirrors the incidence of
AIDS KS, with a seroprevalence rate ofbetween 25-50%
among homosexual men. In other countries such as Italy,
Greece, and Israel, especially Southern Italy, the infection
rate seems to be much higher in the general population,
and is more variable, ranging between 5-35%. In contrast
to North America and Europe, KSHV infection is wide-
spread in the African continent. High seroprevalence rates
between 40 to 50 % have been found in Central, West, as
well as South Africa [41-44]. Therefore, KSHV seropre-
valence tracks very closely with KS, with the highest in-
fection rate in geographic areas where classic or endemic
forms of KS are more common. KS has a particularly
high incidence in Central African countries like the Re-
public of Congo, Uganda, and Zambia; these countries
also have the highest KSHV infection rates in the world
[42]. Very little is known about KSHV infection in China
even though EBV infection was found to be ubiquitous.
There were only two reported studies in China; the study
by Dilnur et al [45] found that KSHV was associated with
KS in China. The study by Du et al [46] in the outskirt of
China in the Xinjiang autonomy region, where there is a
high incidence of HIV-l infection, showed that there was
a high HHV-8 infection rate. The study found KSHV in-
fection varied among individuals of different racial origin,
it was highest in the Khalkhas population at about 48%
and lowest in the Kazak and Han population at over 12%,
but the specimens were screened without dilution and the
reproducibility of the assay was not determined, and the
prevalence among different risk groups was not studied.
Thus, there is a need to perform a systematic comparison
of risk groups using established assays.
PRIMARY EFFUSION LYMPHOMAS
In addition to KS, KSHV has also been associated with
several other AIDS-associated neoplasms, primary effu-
sion lymphomas, and multi-centric Castleman's disease.
Primary effusion lymphoma (PEL) was first identified as
a subset of body-cavity-based lymphomas, which subse-
quently was called PELs [47]. PELs are unique as they
were found to contain KSHV DNA are most frequently
found in men and in AIDS patient. This type of lymphoma
is distinguished from others as having a distinctive
morphology, bridging large cell immunoblastic lymphoma
and anaplastic large cell lymphoma. PELs often present as
lymphomatous effusions in the pleural, peritoneal, and lor
pericardial cavity. These cells usually CD20 negative but
often express CD45 marker but lack B-cell-associated
antigens. PELs are B cell origin with clonal immunoglobu-
lin gene rearrangements. Most PELs are co-infected with
EBV and lack e-myc gene rearrangements. PELs are ex-
tremely rare tumors, and estimated to be about 0.13% of
all AIDS-related malignancies in AIDS patients in the US
[48]. Thus, KSHV-associated lymphomas represent a rare,
distinct pathobiologic category which often, but not always,
associates with an effusion in AIDS patients. The role of
KSHV in the development ofthese lymphomas is not clear
since this type of malignancies is still rare even in the popu-
lations with high KSHV seroprevalence rate. However,
KSHV has always been found in these lymphomas, sug-
gesting that this virus is necessary, but other factors must
be needed for the development of PELs. These factors
could be EBV infection and/or immunosuppression. Re-
cently solid tumor variants with plasmablastic features have
been reported and these tumors tend to be rapidly fatal
although recent data suggests that some PEL lines are quite
sensitive to inhibition ofNF-KB [49].
MULTI-CENTRIC CASTLEMAN'S DISEASE
Multi-centric Castleman's disease (MCD) has also been
associated with KSHV infection. MCD is a rare and poorly
understood B celllymphoproliferative disorder with vas-
cular proliferation in the germinal centers, and is though to
be related to immune dysregulation [50]. KSHV is found
in almost all cases of MCD in AIDS patients and in about
50 % of cases of MCD in HIV negative individuals, sug-
gesting that there is an association between KSHV and
MCD at least in HIV-positive cases [51]. However, the
role of KSHV in the pathobiology of MCD is not well
understood, and it is not clear whether there are any clini-
cal differences between those with and without KSHV.
IMPACT OF HAART ON KS
Since the beginning of the AIDS epidemic in the early
1980's, AIDS-KS has become one of the most common
AIDS-associated malignancies with HIV-infected homo-
sexual males at the highest risk, and those with AIDS had
a 50% lifetime rate of developing KS early in the HIV epi-
demic [52]. However, the rate of AIDS-KS has since
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steadily declined both in the US and Europe [53]. It has
been suggested that the disease may have shifted from an
early disease to a late manifestation during the HIV disease
course. Since the introduction of highly active antiretroviral
therapy, a further major decrease in AIDS-KS was further
observed [54], and therapy has now made AIDS-KS a
relatively rare tumor in treated HIV-infected individuals
[55]. Several studies have shown that there was a marked
decrease in KS incidence since HAART was introduced, a
decline of as high as 80-fold was observed. In addition
regression of KS following treatment has been reported
[4,56-59]. Interestingly, the reduced KS risk was only
observed with HAART, but not with double or single anti-
HIV drugs [60]. Even though the incidence ofKS in the
treated HIV-infected individuals in the western world has
decreased dramatically, in the setting where HAART is
still not widely available, such as sub-Saharan Africa,
AIDS-KS still remains a major problem.
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